Business
TransMedics Reports First Quarter 2025 Financial Results
ANDOVER, Mass., May 8, 2025 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ
About this update from Transmedics Group, Inc.
[{"type":"text","content":"ANDOVER, Mass., May 8, 2025 /PRNewswire/ -- TransMedics Group, Inc. (\"TransMedics\") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, today reported financial results for the quarter ended March 31, 2025.\n\n \n \n \n \n \n \n\n \nRecent Highlights\nTotal revenue of $143.5 million in the first quarter of 2025, a 48% increase compared to the first quarter of 2024Generated net income of $25.7 million or $0.70 per fully diluted share in the first quarter of 2025Raising full year 2025 revenue guidance to $565 million to $585 millionOwned 21 aircraft as of March 31, 2025Announced strategic plan to open design center of excellence and new disposables manufacturing facility in Mirandola, ItalyHosted annual symposium at the International Society of Heart and Lung Transplantation (ISHLT) 45th Annual Meeting & Scientific Session in Boston; highlighted latest design and potential sample size of upcoming next-gen clinical programs10 abstracts and presentations at ISHLT featured OCS™ & NOP™ clinical value\"Overall, we are very pleased with our first quarter performance, which we believe underscores the unique attributes of our business and the ability to deliver strong top and bottom-line financial results,\" said Waleed Hassanein, MD, President and Chief Executive Officer. \"We are confident in our ability to sustain this momentum through 2025 and beyond by remaining laser focused on operational execution and leveraging the unrivaled capabilities of OCS NOP to expand the utilization of available donor organs for transplantation. Ultimately, this will enable us to deliver what we believe to be the best possible clinical outcomes and most cost-efficient therapy for our transplant patients. We are grateful and humbled by the unwavering support of our clinical transplant partners and the resilience of our exceptional team.\"\nFirst Quarter 2025 Financial Results \nTotal revenue for the first quarter of 2025 was $143.5 million, a 48% increase compared to $96.9 million in the first quarter of 2024. The increase was due primarily to the increase in utilization of the Organ Care System (\"OCS\"), primarily in Liver and Heart through the National OCS Program (\"NOP\") as well as additional revenue generated by the addition of TransMedics logistics ...